GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Median PS Value

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Median PS Value : $0.00 (As of Apr. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Sucampo Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2017 was $4.767. Sucampo Pharmaceuticals's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-26), Sucampo Pharmaceuticals's share price is $18.00. Sucampo Pharmaceuticals's Median PS Value is $0.00. Therefore, Sucampo Pharmaceuticals's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Sucampo Pharmaceuticals's Median PS Value or its related term are showing as below:

SCMP's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.8
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Sucampo Pharmaceuticals Median PS Value Historical Data

The historical data trend for Sucampo Pharmaceuticals's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Median PS Value Chart

Sucampo Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sucampo Pharmaceuticals Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sucampo Pharmaceuticals's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sucampo Pharmaceuticals's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's Price-to-Median-PS-Value falls into.



Sucampo Pharmaceuticals Median PS Value Calculation

Sucampo Pharmaceuticals's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=4.767*0
=0.00

10-Year Median PS Ratio is 0.
Sucampo Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.767.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sucampo Pharmaceuticals  (NAS:SCMP) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Sucampo Pharmaceuticals's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=18.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sucampo Pharmaceuticals Median PS Value Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.
Executives
Peter Greenleaf officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell director
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan officer: Sr. Vice Pres., BD & Licensing C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener officer: Chief Science Officer 40 GUEST STREET, BOSTON MA 02135
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp other: Former Officer 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin director 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris officer: Chief Acctg. Officer, Treas. C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Headlines